LOGIN  |  REGISTER
Assertio

GoodRx to Participate in Upcoming Investor Conferences

February 20, 2024 | Last Trade: US$4.35 0.01 -0.23

SANTA MONICA, Calif. / Feb 20, 2024 / Business Wire / GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences:

  • TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2024 at 9:10 a.m. Eastern Time (6:10 a.m. Pacific Time)
  • Barclays 26th Annual Global Healthcare Conference in Miami, FL on Thursday, March 14, 2024 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time)

A live webcast of each of the foregoing events will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following each conference, an archived recording will be available on the Company’s website for at least 30 days.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare providers with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save more than $65 billion and is one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page